Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanh Thi Pham

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Drugs in Context|March 3, 2018
The latest evidence for possible HIV-1 curative strategiesHanh Thi Pham, Thibault Mesplède
Expert Opinion on Pharmacotherapy|January 31, 2019
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implicationsHanh Thi Pham, Thibault Mesplède
Expert Opinion on Investigational Drugs|January 30, 2020
Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1Hanh Thi Pham, Subin Yoo, Thibault Mesplède
The Journal of Infectious Diseases|August 31, 2018
Reply to Achieng and RiedelHanh Thi Pham, Mark E Goring, Thibault Mesplède
Drugs in Context|March 18, 2020
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infectionHanh Thi Pham, Meng A Xiao, Miguel Av Principe, et al.
Journal of Medical Education and Curricular Development|May 15, 2023
Effectiveness of a New Clinical and Communication Curriculum for Medical Students: Result of a Double-Blinded Randomized Controlled Educational TrialSang Ngoc Nguyen, Hanh Thi Pham, Lam Tung Vu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 13, 2019
Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several RetrovirusesHanh Thi Pham, Said Hassounah, Brandon F Keele, et al.
AIDS (London, England)|July 2, 2016
The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravirMaureen Oliveira, Ruxandra I Ibanescu, Hanh Thi Pham, et al.
Mbio|April 6, 2017
The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 IntegrationThibault Mesplède, Jing Leng, Hanh Thi Pham, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2023
The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and IntegrationMeng A Xiao, Jenna Cleyle, Sunbin Yoo, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Drugs in Context|March 3, 2018
The latest evidence for possible HIV-1 curative strategiesHanh Thi Pham, Thibault Mesplède
Expert Opinion on Pharmacotherapy|January 31, 2019
Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implicationsHanh Thi Pham, Thibault Mesplède
Expert Opinion on Investigational Drugs|January 30, 2020
Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1Hanh Thi Pham, Subin Yoo, Thibault Mesplède
The Journal of Infectious Diseases|August 31, 2018
Reply to Achieng and RiedelHanh Thi Pham, Mark E Goring, Thibault Mesplède
Drugs in Context|March 18, 2020
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infectionHanh Thi Pham, Meng A Xiao, Miguel Av Principe, et al.
Journal of Medical Education and Curricular Development|May 15, 2023
Effectiveness of a New Clinical and Communication Curriculum for Medical Students: Result of a Double-Blinded Randomized Controlled Educational TrialSang Ngoc Nguyen, Hanh Thi Pham, Lam Tung Vu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 13, 2019
Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several RetrovirusesHanh Thi Pham, Said Hassounah, Brandon F Keele, et al.
AIDS (London, England)|July 2, 2016
The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravirMaureen Oliveira, Ruxandra I Ibanescu, Hanh Thi Pham, et al.
Mbio|April 6, 2017
The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 IntegrationThibault Mesplède, Jing Leng, Hanh Thi Pham, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2023
The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and IntegrationMeng A Xiao, Jenna Cleyle, Sunbin Yoo, et al.
Pageof 2